Background: Helicobacter pylori eradication therapy is commonly performed to re-
| INTRODUC TI ON
Helicobacter pylori infection is one of the most common triggers of gastric cancer, and gastric cancer is the major cause of cancer deaths. [1] [2] [3] [4] Gastric cancers are the third leading cause of cancer mortality and advanced disease carries a dismal prognosis with a 5-year overall survival rate of less than 5%. 5, 6 Surgery and endoscopic resection at an early stage is still the only chance for cure. 7, 8 Although it has been reported that H. pylori eradication therapy reduces the incidence of gastric cancer and is widely conducted to prevent gastric carcinogenesis, gastric cancers are still diagnosed in patients who received successful eradication therapy. [9] [10] [11] [12] [13] Thus, endoscopic surveillance of gastric cancers after H. pylori eradication is expected to be a beneficial approach for detection.
The endoscopic and histological features of gastric cancers after eradication have been investigated vigorously. [14] [15] [16] To the best of our knowledge, research on gastric cancer deaths after successful H. pylori eradication therapy is insufficient. Therefore, we examined the prognosis of gastric cancer diagnosed after successful H. pylori eradication therapy.
| ME THODS

| Patients
Gastric cancer patients diagnosed at Toyoshima Endoscopy Clinic were analysed retrospectively using an endoscopic database and The interval since last endoscopy was defined as the interval between the endoscopy during which the gastric cancer was detected and the previous endoscopy.
| Clinicopathological assessment
| H. pylori infection status
Helicobacter pylori infection was confirmed when any one of the following tests was positive; 13 therapy history and gastric atrophy). 19 We removed groups (3) and (4) from the analysis comparing the effect of H. pylori eradication.
| Statistical analysis
All statistical analyses were performed using JMP10 software (SAS Institute, Cary, NC, USA). Welch's t test was used to compare the means of continuous variables. Comparisons of nominal variables were performed using the χ 2 test or Fisher's exact test, as appropriate. The incidence of all-cause death was evaluated using the Kaplan-Meier method, and the statistical significance of the differences was evaluated by log-rank test. All-cause death was the primary endpoint, and data were censored at the final visit.
Additional endpoint was gastric cancer death. Odds ratios (OR) with 95% confidence intervals (CI) were used as a measure of association and were adjusted using unconditional logistic regression models.
A two-sided P -value of <.05 was considered to indicate statistical significance.
TA B L E 1 Characteristics of the 160 gastric cancer patients
Characteristics Total (n = 160) Death (n = 11) Survival (n = 149) P 
| Gastric cancer in the H. pylori persistent infection group vs the successful eradication group
Next, we examined the influence of successful H. pylori eradication therapy on all-cause death and gastric cancer-specific death in gastric cancer patients. We excluded the 6 uninfected gastric cancer patients (who had no H. pylori infection or history of eradication therapy and gastric atrophy) from this analysis because this small fraction of gastric cancer patients displayed multi-fractional carcinogenesis without H. pylori infection. 20 We also excluded the 12 patients in the H. pylori spontaneous eradication group (no H. pylori infection patients without history of eradication therapy with atrophic gastritis). 21, 22 As shown in Table 2 , 53 gastric cancer patients were diagnosed after successful H. pylori eradication therapy (the mean interval between the eradication treatment and the detection of gastric cancer the successful H. pylori eradication group (P = .0022 and P < .0001, respectively). The proportion of patients who received curative endoscopic therapy for gastric cancer and screening endoscopy in the 2 years prior to gastric cancer diagnosis was higher in the successful eradication group (P = .0022 and P < .0001, respectively).
Kaplan-Meier analysis of the proportions of patients free of allcause death in the H. pylori persistent infection group and successful H. pylori eradication group is shown in Figure 1A . A significant difference was found for the incidence of all-cause death in these 2 groups using a log-rank test (P = .0139). Kaplan-Meier analysis of the proportions of patients free of gastric cancer death in the H. pylori persistent infection group and successful H. pylori eradication group is shown in Figure 1B . A significant between-group difference was also found using a log-rank test (P = .0396).
| Associated factors of gastric cancer stage
We conducted a multivariate analysis of the 142 patients (89 in the persistent infection group and 53 in the successful eradication therapy group) shown in 
| D ISCUSS I ON
We examined the prognosis of gastric cancer patients diagnosed after successful H. pylori eradication therapy and found that these gastric cancer patients showed better prognosis than the gastric cancer patients who did not undergo successful eradication therapy.
In this study, 86.8% of gastric cancers diagnosed after successful eradication therapy were the intestinal type (Table 2) , and it was more frequent than the diffuse type. This is consistent with past reports. 10, 13, 23 Our study revealed that gastric cancer patients diagnosed after successful eradication therapy showed early stage cancer at diagnosis and high a proportion of them received curative endoscopic therapy ( Table 2) . Decreased Prostate Stem Cell Antigen (PSCA) expression has been documented in gastric cancer 24 and we recently showed that H. pylori eradication therapy resulted in increased PSCA expression. 25 The other molecular biological effects of H. pylori eradication treatment on stomach cancer carcinogenesis and progression, which could not be evaluated in this research, have been vigorously investigated. [26] [27] [28] Researchers have also reported that after H. pylori eradication, gastric atrophy decreases gradually and significantly. 29, 30 Although the inhibitory effect on the development of gastric cancer following H. pylori eradication, which alters the biological characteristics and surrounding environment of the gastric cancer (as described above), is expected to improve prognosis, the present study failed to show this. Instead, we showed that patients who received 
TA B L E 2 (Continued)
successful H. pylori eradication therapy tended to undergo endoscopy in the 2 years prior to gastric cancer diagnosis ( Table 2 ) and "endoscopy within 2 years before cancer diagnosis" contributed to early diagnosis of gastric cancer (Table 3) . Representative guidelines recommend H. pylori eradication to reduce the gastric cancer incidence, and regular endoscopic surveillance for early detection and early treatment. 31, 32 We believe our results support the important role of endoscopic surveillance after eradication therapy.
There were limitations to our study. First, the study participants were from a single outpatient endoscopic clinic. Future large-scale research is needed. Second, we could not distinguish whether the gastric cancers diagnosed after eradication had occurred after eradication or existed before the eradication. Third, patients did not randomly receive H. pylori eradication therapy, and thus, there were background differences in the patients who received therapy and those who did not, such as the interval between endoscopic examinations. We are planning to conduct a further analysis that involves a greater number of cases and matches the backgrounds of the eradication group and natural history group as closely as possible.
| CON CLUS ION
In conclusion, we found that patients with gastric cancer, diagnosed after successful H. pylori eradication therapy, had a low mortality rate. Although the mortality rate was significantly decreased in the successful H. pylori eradication therapy group, the "endoscopy within 2 years before cancer diagnosis" was a confounding factor.
That periodic endoscopy was associated with eradication treatment suggest that it may also lead to a reduction in the mortality rate and is therefore recommended.
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